{"nctId":"NCT01315678","briefTitle":"Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections","startDateStruct":{"date":"2012-02-29","type":"ACTUAL"},"conditions":["Pseudomonas Aeruginosa Infection"],"count":302,"armGroups":[{"label":"Arikayce™","type":"EXPERIMENTAL","interventionNames":["Drug: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer."]},{"label":"TOBI®","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tobramycin inhalation solution using a PARI LC® Plus nebulizer."]}],"interventions":[{"name":"Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.","otherNames":[]},{"name":"Tobramycin inhalation solution using a PARI LC® Plus nebulizer.","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Written informed consent or assent\n* Confirmed diagnosis of CF\n* History of chronic infection with Pseudomonas aeruginosa\n* Sputum culture positive for Pseudomonas aeruginosa at Screening\n* FEV1 ≥ 25% of predicted value at Screening\n\nKey Exclusion Criteria:\n\n* FEV1 \\<25% of predicted at Screening\n* History of major complications of lung disease within 8 weeks prior to Screening\n* Hemoptysis of ≥60 mL in a 24-hour period within 4 weeks prior to Screening\n* History of positive culture for Burkholderia cepacia within 2 years prior to Screening\n* History of pulmonary tuberculosis or non-tuberculous mycobacterial lung disease treated within 2 years prior to Screening or requiring treatment at the time of screening\n* History of Allergic Broncho-Pulmonary Aspergillosis or any other condition requiring systemic steroids at a dose ≥ equivalent of 10 mg/day of prednisone within 3 months prior to Screening\n* Presence of any clinically significant cardiac disease\n* History of lung transplantation\n* Daily, continuous oxygen supplementation or nighttime supplemental oxygen requirement of greater than 2 L/min\n* Administration of any investigational products within 8 weeks prior to study Day 1\n* Smoking tobacco or any substance within 6 months prior to screening or anticipated inability to refrain from smoking throughout the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pulmonary Function Test: Forced Expiratory Volume in 1 Second (FEV1)","description":"Relative Change (%) from baseline to end of study (Day 168) in FEV1 (1 second)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"13.930"},{"groupId":"OG001","value":"1.67","spread":"16.050"}]}]}]},{"type":"SECONDARY","title":"Pumonary Function Test: Forced Expiratory Volume in 1 Second (FEV1)","description":"Relative changes (%) from baseline to Study Days 14, 28, 57, 84, 113, 140, 168 in FEV1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.59","spread":"13.332"},{"groupId":"OG001","value":"6.64","spread":"15.669"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":"14.745"},{"groupId":"OG001","value":"3.32","spread":"14.715"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.49","spread":"12.319"},{"groupId":"OG001","value":"0.70","spread":"14.510"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"14.350"},{"groupId":"OG001","value":"3.59","spread":"14.642"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":"12.028"},{"groupId":"OG001","value":"0.42","spread":"14.434"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"15.299"},{"groupId":"OG001","value":"1.37","spread":"16.563"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"14.326"},{"groupId":"OG001","value":"1.58","spread":"15.970"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing a Pulmonary Exacerbation","description":"Number of participants experiencing a pulmonary exacerbation measured by number with event and number censored","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants to First Antipseudomonal Antibiotic Treatment for Pulmonary Exacerbation","description":"Number of participants to first antipseudomonal antibiotic treatment for pulmonary exacerbation measured by number with event and number censored","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants to First All Cause Hospitalization","description":"Number of participants to first all cause hospitalization measured by number with event and number censored","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"117","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Density (Log CFU) in Pseudomonas Aeruginosa in Sputum","description":"Change in density (Log CFU) from baseline in Pseudomonas aeruginosa in sputum","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.872","spread":"1.8806"},{"groupId":"OG001","value":"6.510","spread":"2.3202"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.124","spread":"2.0542"},{"groupId":"OG001","value":"-1.663","spread":"2.4017"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.208","spread":"2.1594"},{"groupId":"OG001","value":"-1.453","spread":"2.4440"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.210","spread":"1.9874"},{"groupId":"OG001","value":"-0.098","spread":"1.7446"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.945","spread":"2.2223"},{"groupId":"OG001","value":"-1.182","spread":"2.6914"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.613","spread":"2.1928"},{"groupId":"OG001","value":"-0.135","spread":"2.3461"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.440","spread":"2.4357"},{"groupId":"OG001","value":"-1.315","spread":"2.2300"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.725","spread":"2.0073"},{"groupId":"OG001","value":"-0.136","spread":"2.1750"}]}]}]},{"type":"SECONDARY","title":"Relative Percent (%) Change in Respiratory Symptoms as Measured by the CFQ-R","description":"Quality of Life was measured by the absolute change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory scale. Disease specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms in patients with a diagnosis of cystic fibrosis. Scores range from 0 to 100, with higher scores indicating better health. Scores for each Health Related Quality of Life (HRQoL) domain; after recoding, each item is summed to generate a domain score and standardized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.65","spread":"2.995"},{"groupId":"OG001","value":"8.81","spread":"3.019"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.54","spread":"3.363"},{"groupId":"OG001","value":"11.03","spread":"3.419"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.00","spread":"3.120"},{"groupId":"OG001","value":"7.97","spread":"3.146"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.20","spread":"3.079"},{"groupId":"OG001","value":"8.55","spread":"3.111"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.58","spread":"3.323"},{"groupId":"OG001","value":"5.03","spread":"3.290"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.84","spread":"3.060"},{"groupId":"OG001","value":"6.10","spread":"3.079"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.06","spread":"3.784"},{"groupId":"OG001","value":"8.07","spread":"3.790"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":148},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","Nasopharyngitis","Haemoptysis","General disorders","Cough"]}}}